Healthcare

Omanta

Website
Founded 2026Origin source ↗Checked 2026-09-15

Overview

Omanta is a personalized research lab for patients who have exhausted standard options, want to prepare proactively for recurrence, or are living with an unresolved diagnosis.

We direct the full operational infrastructure, personnel, expertise, and technology of a large research program toward understanding and addressing the challenges of individual patients across oncology, rare disease, and undiagnosed conditions.

For clinicians, we act as a collaborative partner, providing a living roadmap for ongoing patient care built on a rigorous and evolving scientific evidence base.

We fully operationalize patient-specific research programs, covering tissue logistics, diagnostic follow-up, data integration, multiomic analysis, therapeutic strategy development, and more.

Omanta brings context and clarity to complex cases, helping clinicians see more of the scientific picture as they decide how best to care for their patients.

Company description As recorded 2026-11-08

Founders & team

Previously ClinSIGHT AI

Company history As recorded 2026-11-08

Alfredo Gonzalez

Founder/CEO

Co-Founder and CEO of Omanta. PhD in Cancer Bioinformatics from UCLA, biomedical researcher at Broad Institute and Harvard. Spearheaded personalized therapeutic campaigns for patients creating personalized vaccines, immunotherapies, and radioligands. 10+ years in personalized medicine. Fueled by the belief that the future of Health is deeply personalized.

Founder profile As recorded 2026-09-15

Ranad Humeidi

Founder and Chief Scientific Officer

Co-founder & CSO at Omanta, working with patients to turn frontier science into personalized treatment strategies. Harvard Chemical Biology PhD in 3 years; identified a druggable ulcerative colitis mechanism that led to a multimillion-dollar GSK collaboration. Built and directed a multimillion-dollar rare cancer program for one patient, coordinating researchers, physicians, biotechs, and drug developers. Led strategies for 12+ complex patients after standard options were exhausted.

Founder profile As recorded 2026-09-15
6team members reported
Source-reported As recorded 2026-09-15

Founded 2026 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedSan Francisco, CA, USA
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year